Lara Dorfman joins Nonprofit Biotech Odylia Therapeutics

Lara Aronoff Dorfman joins Odylia Therapeutics as the Director of Business Development.  Her focus for this unique nonprofit biotech company will be raising capital through philanthropy, primarily from foundations and corporate giving.  Increased funds will allow Odylia to have a greater impact on shifting the way gene therapies are brought to market, ultimately bringing life changing treatments to people living with rare diseases regardless of prevalence or commercial interest.  Lara states, “Odylia is a new and premier choice for philanthropists truly looking to see change in the rare disease, gene therapy and/or retinal health spaces in a non-traditional way. We have an amazing opportunity to share.”

Lara has helped nonprofits thrive for over 20 years.  As an Executive Director and through consulting roles, Lara has built organizational capacity in nonprofits and philanthropic institutions through resource development and strategic planning. She received her Bachelor’s Degree from the University of Maryland and a Master’s Degree in Social Work from Georgia State University with a concentration in Nonprofit Management.  

“We are excited to have Lara join Odylia,” said Harrison Brown, Chief Scientific Officer at Odylia. “Her expertise in the area of nonprofits, in addition to our core competencies in gene therapies and business, compliments our team and positions us for our next phase of growth.”